- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT03913000
A Study to Evaluate ID-085 in People With Mild, Moderate, and Severe Kidney Disease
Open-label, Phase 1 Study to Investigate the Effects of Mild, Moderate, and Severe Renal Function Impairment on the Pharmacokinetics, Safety, and Tolerability of a Single Dose of ID-085
Visão geral do estudo
Tipo de estudo
Inscrição (Real)
Estágio
- Fase 1
Contactos e Locais
Locais de estudo
-
-
-
Kiel, Alemanha, 24105
- CRS Clinical Research Services Kiel GmbH
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
All subjects:
- Signed informed consent in a language understandable to the subject prior to any study-mandated procedure.
- Male and female subjects aged between 18 and 79 years (inclusive) at screening.
- Body mass index (BMI) of 18.0 to 34.0 kg/m2 (inclusive) at screening. Body weight of at least 50 kg.
- Women of childbearing potential must have a negative serum pregnancy test at screening and a negative urine pregnancy test on Day-1. They must consistently and correctly use (from at least first dosing, during the entire study, and for at least 30 days after last study treatment intake) a highly effective method of contraception with a failure rate of < 1% per year and must use condoms, diaphragm or cervical cap with spermicide, or be sexually abstinent. Hormonal contraceptive must be initiated at least 1 month before study treatment administration.
Renal function impairment subjects:
• At screening and on Day -1, the stage of renal function impairment will be defined by Creatinine Clearance (CLcr) by the Cockcroft-Gault (C-G) equation:
- Mild renal function impairment: CLcr 60-89 mL/min (Group A).
- Moderate renal function impairment: CLcr 30-59 mL/min (Group B).
- Severe renal function impairment: CLcr <30 mL/min (Group C).
The stage of renal impairment will need to be confirmed at Day -1 and the CLcr values on Day -1 will need to remain within ± 25% of the screening value.
Healthy subjects:
• Normal renal function confirmed by a CLcr ≥ 90 mL/min. Normal renal function will need to be confirmed at Day -1 and the CLcr value on Day -1 will need to remain within ± 25% of the screening value.
Exclusion Criteria:
All subjects:
- Pregnant or lactating women.
- Known hypersensitivity to ID-085 or treatments of the same class, or any of its excipients.
- Known hypersensitivity or allergy to natural rubber latex.
- Any circumstances or conditions, which, in the opinion of the investigator, may affect full participation in the study or compliance with the protocol.
Renal function impairment subjects:
- Subjects on dialysis.
- Hemoglobin concentration < 9 g/dL.
- Serum potassium concentration > 6 mmol/L.
- Platelet count < 100 × 10^6/mL.
- History of severe renal stenosis.
- History of clinically relevant bleeding disorder.
- Gastrointestinal bleeding within 2 weeks prior to screening.
- Presence of unstable diabetes mellitus.
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Outro
- Modelo Intervencional: Atribuição sequencial
- Mascaramento: Nenhum (rótulo aberto)
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: ID-085 single dose
Administration of the study treatment 200 mg to renally impaired subjects will be done by severity, starting with group A (mild), and followed by group B (moderate), C (severe) and D (healthy subjects).
|
Hard capsules for oral administration formulated at a strength of 200 mg
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Area under the plasma concentration-time curve (AUC) from time zero to time t of the last measured concentration above the limit of quantification (AUC0-t)
Prazo: Up to Day 3 after treatment administration
|
Will be derived by non-compartmental analysis of the plasma concentration-time profiles
|
Up to Day 3 after treatment administration
|
|
The plasma AUC from zero to infinity (AUC0-inf), calculated with the apparent λz
Prazo: Up to Day 3 after treatment administration
|
Will be derived by non-compartmental analysis of the plasma concentration-time profiles
|
Up to Day 3 after treatment administration
|
|
The maximum plasma concentration (Cmax)
Prazo: Up to Day 3 after treatment administration
|
Will be derived by non-compartmental analysis of the plasma concentration-time profiles
|
Up to Day 3 after treatment administration
|
|
The time to reach Cmax (tmax)
Prazo: Up to Day 3 after treatment administration
|
Will be derived by non-compartmental analysis of the plasma concentration-time profiles
|
Up to Day 3 after treatment administration
|
|
Apparent total body clearance (CL/F)
Prazo: Up to Day 3 after treatment administration
|
Will be derived by non-compartmental analysis of the plasma concentration-time profiles
|
Up to Day 3 after treatment administration
|
|
Apparent volume of distribution (Vz/F)
Prazo: Up to Day 3 after treatment administration
|
Will be derived by non-compartmental analysis of the plasma concentration-time profiles
|
Up to Day 3 after treatment administration
|
Colaboradores e Investigadores
Patrocinador
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Real)
Conclusão do estudo (Real)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- ID-085-103
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .